Previous post Next post

Can Swiss pharma giant Roche reshape the obesity market?

After missing the first wave of GLP-1 blockbusters, Roche is investing billions in a new generation of obesity treatments. With Novo Nordisk and Eli Lilly dominating the market, can the Swiss pharma giant still find a foothold? In early March, Swiss pharma giant Roche put out some good news about the obesity drug candidate Petrelintide it’s developing with Danish biotech Zealand Pharma. In a phase II trial, the medication, injected once a week, met its primary endpoint of statistically significant weight loss. Participants shed on average 10.7% of their body weight and sustained the loss to 42 weeks with only mild side-effects. But investors weren’t impressed. Shares of Zealand Pharma dropped by a record 35% the day after the announcement, while Roche fell around 3%. In today’s world of obesity drugs, 10.7% weight loss is hardly remarkable. Users of Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide) have reported losing 15-20%. In clinical trials of Zepbound ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2026/04/swiss-pharma-giant-roche-reshape-obesity-market/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.